At the news
? BEARISHIMPACT 8/10 8-K filed Mar 5, 2026 at 06:03 ET
Moderna entered into a settlement agreement with Arbutus Biopharma and Genevant Sciences to resolve all ongoing patent infringement litigation related to its vaccines, including Spikevax and mRESVIA. Moderna will make a $950 million noncontingent payment by July 8, 2026, and may face an additional $1.3 billion contingent payment depending on the outcome of its appeal regarding U.S. government contract protections under 28 U.S.C. 1498.
- Moderna agreed to pay $950 million noncontingent lump sum to Arbutus/Genevant by July 8, 2026.
- An additional contingent payment of up to $1.3 billion may be required if Moderna loses its appeal on 28 U.S.C. 1498 defense.
- The settlement resolves all worldwide litigation related to Spikevax, mRESVIA, and provides certainty for Moderna's infectious disease portfolio with no future royalties.
- If the Federal Circuit rules that 1498 bars infringement claims for some vaccine doses, the contingent payment will be prorated.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access